

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
17 August 2023 (17.08.2023)



(10) International Publication Number
WO 2023/152194 A1

(51) International Patent Classification:
C12N 15/113 (2010.01)

(21) International Application Number:
PCT/EP2023/053136

(22) International Filing Date:
08 February 2023 (08.02.2023)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/308,167 09 February 2022 (09.02.2022) US
63/320,381 16 March 2022 (16.03.2022) US
63/395,246 04 August 2022 (04.08.2022) US
63/420,195 28 October 2022 (28.10.2022) US

(71) Applicant: **SILENCE THERAPEUTICS GMBH**
[DE/DE]; Robert-Rössle-Strasse 10, 13125 Berlin (DE).

(72) Inventors: **RIDER, David**; Robert-Rössle-Strasse 10, 13125 Berlin (DE). **SWERDLOW, Daniel**; 27 Eastcastle Street, London Greater London W1W 8DH (GB). **CAMPION, Giles**; 27 Eastcastle Street, London Greater London W1W 8DH (GB). **SCRIMGEOUR, Alison**; 27 Eastcastle Street, London Greater London W1W 8DH (GB). **RAMBARAN, Curtis**; 27 Eastcastle Street, London Greater London W1W 8DH (GB). **WILSON, Rosamund**; Granary House, 4 Granary Close, East Grafton, Marlborough Wiltshire SN8 3UA (GB). **MACHACEK, Matthias**; Henric Petri-Strasse 6, CH-4051 Basel (CH). **SCHULTHESS, Pascal**; Henric Petri-Strasse 6, CH-4051 Basel (CH). **WADE, James**; Henric Petri-Strasse 6, 4051 Basel (CH).

(74) Agent: **MEWBURN ELLIS LLP**; Aurora Building, Counterslip, Bristol Avon BS1 6BX (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ,

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(54) Title: THERAPEUTIC INHIBITION OF LPA EXPRESSION

(57) Abstract: The invention relates to the therapeutic inhibition of LPA gene expression, and in particular to effective doses and dosage regimes for the therapeutic use of the SLN360 molecule, in the prophylaxis or treatment of conditions associated with elevated levels of Lp(a). Such conditions include stroke, atherosclerosis, thrombosis, and cardiovascular diseases such as coronary heart disease and aortic stenosis.

WO 2023/152194 A1